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Abstract
Background: Post-operative infections are frequent after radical cystectomy with urinary diversion surgery (UDS).
Reduction of post-operative infections necessitates appropriate peri-operative antimicrobial prophylaxis targeting
causative bacteria. We assessed the incidence and microbiology of infections in the 30-day post-operative period
after UDS and investigated effectiveness of the currently used peri-operative antibacterial prophylaxis.
Methods: Retrospective cohort study of all patients undergoing UDS in a tertiary university medical center from
January 2014 until September 2016. Antibiotic prophylaxis consisted of cefazolin plus metronidazol according to the
Dutch national guideline. Primary outcome was the incidence of post-operative infections within 30 days. Risk
factors for post-operative infections and antimicrobial susceptibility profiles of cultured bacteria were also assessed.
Results: 147 patients were included. 69 patients (46.9%) had 82 post-operative infections, 27 of which were patients
with bacteremia (18.4%). Highest incidence of infections was on day 4–5 and on day 8–10 postoperatively. The second
peak was associated with ureteral stent removal. 4.8% of 147 study patients developed bacteremia 24 h after stent
removal, which counted for 25.9% of all bacteremia episodes found in this study. Enterobacteriaceae were cultured in
67.9% of blood cultures and were only highly susceptible to ciprofloxacine, piperacillin-tazobactam (90%), meropenem
and gentamicin (100%). Multivariate logistic regression analysis showed orthotopic Hautmann neobladder to be
associated with increased infections complications: odds ratio 4.1 (95% confidence interval 1.6–10.5), p = 0.03.
Conclusions: The incidence of infections after radical cystectomy is high and particularly ureteral stent removal was
associated with both bacteremia and complicated urinary tract infections. Based on the results of this study, antibiotic
prophylaxis might need to be broadened for patients undergoing radical cystectomy. Further research is required to
investigate whether current guidelines need to be altered concerning administration of antibiotic prophylaxis just
before stent removal.
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Background
Ileal conduit (IC) and orthotopic Hautmann Neobladder
(NB) are two types of urinary diversion surgery (UDS)
that are frequently performed after radical cystectomy.
In both types of UDS, the ureters are attached to the IC
or NB using temporal ureteral stents to assure patency
and prevent stenosis while healing. The UDS procedure
is associated with increased risk of bacteremia, compli-
cated urinary tract infection (cUTI) and surgical site infec-
tion (SSI) [1]. The first 30 days, infections contribute
significantly to post-operative morbidity [2, 3], which can
be explained by multiple comorbidities as well as by the
complex surgery that involves attaching part of the colo-
nized gastro-intestinal tract to the sterile urinary tract [4].
Up until now, several studies focused on the incidence
of early (< 30 days) post-operative infections [4–11].
Overall infectious complication rates in these studies
ranged from 10 to 41% [7, 9, 11]. Of these infectious
complications, bacteremia was reported in 5 to 17% of
the patients [9–11], cUTI was reported in 4 to 36% of
the patients [5, 9–11] and SSI was reported in 8 to 33%
of patients [4, 6–9, 11] after UDS, even when
peri-operative antimicrobial prophylaxis was used. Al-
though some of these studies reported on the causative
bacteria [4, 5, 8–10], we found that only a few studies
partially provided information on antimicrobial suscepti-
bility of the cultured bacteria [4, 8, 9]. Particularly in the
era of increasing antimicrobial resistance, susceptibility
profiles provide an important pillar in the correct use of
antimicrobial prophylaxis [7, 12]. The recommended
guideline-based peri-operative antimicrobial prophylaxis
for UDS in the Netherlands consists of cefazolin plus
metronidazol [13]. Cefazolin is one of the most pre-
scribed (40%) prophylactic antibiotics for radical cystec-
tomy in the United States as well [14]. However, the
same large cohort study showed that a penicillin-based
regimen with a beta-lactamase inhibitor was associated
with the least post-operative complications [14], suggest-
ing increased gram-negative coverage is necessary in the
era of increasing resistance.
Guidelines [13, 15] advise not to extend the prophy-
laxis beyond 24 h after surgery, which is further sup-
ported by a recent study [14]. Interestingly, none of the
guidelines specifically recommends on the need and type
of antibiotic prophylaxis during ureteral stent removal
after UDS [15–17]. Ureteral stent removal is typically
performed at least a week after UDS and involves ma-
nipulation in a non-sterile environment attached to the
urological tract, which might predispose to infections,
similar to manipulation of an obstructed common bile
duct [18]. European [15] and American guidelines [16] do
recommend antibiotic prophylaxis for patients undergoing
cystourethroscopy (low quality of evidence) based on a
few studies that assessed effectiveness of prophylactic
antibiotics during upper urinary tract stone treatment, but
this might not be representative to ureteral stent removal
after UDS.
Given these shortcomings, the aim of this study was to
ascertain the efficacy of antimicrobial prophylaxis by in-
vestigating the incidence and antibiotic susceptibility of
causative micro-organisms of post-operative infections
after IC or NB urinary diversion surgery. Additionally,
we specifically investigated the incidence and microbiol-
ogy of infections after ureteral stent removal.
Methods
We conducted a retrospective cohort study in the Rad-
boud university medical center, a university hospital in
the Netherlands performing 80–100 radical cystectomies
per year, by using a prospective database of patients
undergoing radical cystectomy followed by UDS.
Inclusion criteria were patients aged ≥18 years and
undergoing either IC or NB diversion between January
2014 and September 2016 in the Radboud university
medical center. Exclusion criteria were an active
pre-operative infection, defined as the presence of signs
of overt infection, or the prescription of a therapeutic
course of antibiotics.
Preparation of patients undergoing UDS consisted of
bowel preparation using an osmotic laxative and enemas
starting one day prior to surgery. Antibiotic prophylaxis
protocol according to the Dutch national guideline con-
sisted of one dose of cefazolin 1000mg and metronidazole
500mg administered intravenously prior to incision [17].
In the Dutch guideline no antibiotic prophylaxis is recom-
mended during ureteral stent removal, also no prolonged
post-operative prophylaxis is recommended [17]. For a
cefazolin dose to be scored as optimal guideline-adherent
in our regression analyses, a repeat administration was re-
quired in case of prolonged surgery (> 4 h), heavy blood
loss (> 2 L), and a double dose in case of a body mass
index (BMI) > 35 kg/m2 or bodyweight > 120 kg [19]. Re-
moval of the ureteral stents was generally performed on
two consecutive days, on day 7 and 8 in case of IC and on
day 9 and 10 in case of NB after radical cystectomy.
Data of interest were extracted from the electronic med-
ical record (EPIC) and entered in CastorEDC, a licensed
online data collection directory for medical research. The
following patient characteristics were collected: sex, age,
length, weight, body mass index, American Society of Anes-
thesiologists (ASA) score, Charlson Comorbidity Index
(CCI) score, indication for surgery and T-staging in the case
of bladder cancer, previous chemotherapy, and carrier state
of a multidrug resistant micro-organism (MDRO) (methi-
cillin-resistant Staphylococcus aureus, vancomycin-resistant
enterococci, bacteria containing plasmid-mediated AmpC
beta-lactamases, extended-spectrum beta-lacamase produ-
cing Enterobacteriaceae, or carbapenemase-producing
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Enterobacteriaceae). Peroperative variables that were col-
lected included duration of surgery, blood loss, timing and
dosage of antibiotic prophylaxis and presence of nephrost-
omy or double-J catheters. Post-operative variables that
were collected were (timing of ) infections, length of
stay and mortality. Table 1 shows the definitions used
to classify infections.
The primary outcome measurement was the incidence
of post-operative infections either microbiologically con-
firmed (bacteremia and cUTI) or clinically diagnosed
(surgical site infection [SSI] [20]) within 30 days after
radical cystectomy (Table 1). These infections were
chosen since these can be prevented with preoperative
antibiotic prophylaxis. A positive urine culture without
concomitant bacteremia in a febrile patient shortly after
UDS not necessarily indicates a cUTI, but excluding
these patients would underestimate the incidence. Fur-
thermore, the new urinary reservoir is the main portal of
entry and the susceptibility of the residing bacteria
should guide prophylaxis and empiric treatment. Pa-
tients with both a positive blood culture and a positive
urine culture taken on the same day (± 1 day) were
scored as “bacteremia” and not as “cUTI”. Secondary out-
come measurements were timing of these infections with
a specific interest in the relationship with ureteral stent re-
moval, the susceptibility profiles of the causative microor-
ganisms, and risk factors for infections within 30 days.
Identification and antimicrobial susceptibility test of
the bacteria isolated from post-operative urine and blood
cultures were collected from the laboratory information
management system (Glims, MIPS, Gent, Belgium).
Identification of the bacteria was performed by
MALDI-TOF MS (MALDI Biotyper, Bruker, Daltonics,
Bremen, Germany). Coagulase-negative staphylococci
and viridans streptococci were considered not clinically
relevant and were excluded from the analysis. Anti-
microbial susceptibility testing was performed with
Phoenix (BD Bioscience, Erembodegem, Belgium) and
E-test (BioMérieux, AB Biodisk, Solna, Sweden) in ac-
cordance with European Committee on Antimicrobial
susceptibility testing (EUCAST) methodology. Minimal
inhibitory concentration (MIC) values were interpreted
and categorized (S, I, and R) according to EUCAST clin-
ical breakpoint table version 7.1. Antimicrobial suscepti-
bility test results for Enterobacteriaceae included
amoxicillin (AMX), amoxicillin-clavulanic acid (AMC),
piperacillin-tazobactam (PTZ), ceftriaxone (CRO), ceftazi-
dime (CAZ), ciprofloxacin (CIP), trimethoprim-
sulfamethoxazole (SXT), meropenem (MEM), and genta-
micin (CN). Susceptibility to cefazolin was not assessed
since antimicrobial susceptibility EUCAST breakpoints for
cefazolin for Enterobacteriaceae do not exist. Susceptibility
testing for enterococci included AMX and vancomycin
(VAN). Susceptibility testing for staphylococci included
cefoxitin (screening test for methicillin susceptibility), and
for Pseudomonas aeruginosa CIP, CAZ, CN, and MEM. In
the analysis of susceptibility profiles we selected the first
isolate per species per patient to avoid bias due to multiple
testing. In case more than one bacterial species was isolated
from a culture, all uropathogens with a unique resistance
pattern were included.
Statistical analysis was performed using SPSS 22.0.
Continuous variables were analyzed using students
t-test in case of normal distribution, and
non-parametric tests in case of non-normal distribu-
tion. Categorical variables were analyzed using
Chi-Square or Fisher’s exact test. We performed
multivariate logistic regression analysis to test for
risk factors for infection. Prognostic factors associ-
ated with a p-value of < 0.20 in univariate analysis
were included in multivariate analysis. A 2-sided
p-value of ≤0.05 was considered statistically
significant.
The regional institutional review board approved
this study and waived the requirement to obtain in-
formed consent.
Results
Patient characteristics
Of the 200 patients who underwent radical cystec-
tomy, 36 did not receive surgery at our institution. Of
the 164 remaining patients, 17 patients had an active
infection at time of surgery and were excluded. The
remaining 147 patients were included in our study. A
total of 120 patients underwent IC diversion (82%),
while 27 (18%) received a NB. Patients that received a
NB were younger than those who received an IC di-
version (mean age 57.9 [SD 9.55] vs 67.0 [SD 10.1]
years, respectively; p = 0.004) and had a different dis-
tribution of ASA scores (1 [IQR 1–1] vs 1 [IQR 1–2];
p = 0.047). Table 2 shows the demographic and clinical
characteristics of the included patients.
Table 1 Definitions used for post-operative infectious complications
Complicated urinary tract
infection
Temperature≥ 38.5 °C and a positive urine culture (≥105 CFU/ml and leucocytes in gram stain) without a positive
blood culture or SSI
Surgical site infections CDC criteria [20]
Bacteremia Temperature≥ 38.5 °C and a positive blood culture with or without a positive urine culture
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Incidence of post-operative infections
During the 30-day post-operative period 82 post-operative
infections occurred in 69 of 147 patients (46.9%) (Fig. 1).
We found 27 episodes of bacteremia (in 27 patients
[32.9%]), 43 complicated UTIs (in 41 patients [52.4%], and
12 SSIs (in 11 patients [14.6%]). Twelve patients had more
than one infection during the study period. The incidence
of post-operative infections peaked on day 4–5 and day
8–10 post-operatively (Fig. 1). The highest incidence of
bacteremia was on day 7–10, whereas SSIs only occurred
from day 5 onwards and were evenly distributed during
the 30-day follow-up period.
Bacteremia
Twenty-seven of 147 patients had bacteremia during the
30-day post-operative period (18.4%). Of 27 patients
with positive blood cultures, in 17 patients both the
blood culture and urine culture contained identical bac-
teria, in 7 patients no urine cultures were performed,
and in 3 patients the bacteria found in the blood culture
differed from the bacteria found in the urine culture.
The blood cultures performed grew a total of 28 bacteria
(Table 3). Enterobacteriaceae represented the largest
group (67.9%), followed by enterococci (18%), S. aureus
(11%) and B. fragilis (4%). In one patient, the blood cul-
ture contained both Klebsiella pneumoniae and Proteus
mirabilis. Susceptibility profiles of the Enterobacteria-
ceae plus P. aeruginosa are shown in Fig. 2a. Enterococci
were susceptible to AMX in 80% of isolates and suscep-
tibility to VAN was 100%. All S. aureus isolates were
methicillin susceptible.
Complicated UTI
Forty-one of 147 patients had at least one episode of
cUTI during the 30-day post-operative period (27.9%).
The 43 urine cultures of these 41 patients grew 66
micro-organisms (range of cultured bacteria within 1 cul-
ture: 1–3), of which 41 (62.1%) were Enterobacteriaceae
(Table 3). The susceptibility profiles of the
Table 2 Demographic and clinical characteristics of the 147
included patients
Variable n (%) or mean ± SD
Sex, males 112 (76.2)
Age, years 65.4 (10.6)
BMI, kg/m2 26.4 (4.1)
(Previous) smoker 68 (46.3)
Hypertension 79 (53.7)
Diabetes mellitus 16 (10.9)
Nephrostomy catheter 14 (10.1)
ASA class
ASA class 1 20 (13.6)
ASA class 2 91 (61.9)
ASA class 3 36 (24.5)
Indication
Bladder cancer 123 (81.6)
Stage T ≥ T2 73 (59.3)
Other malignancy 13 (8.8)
Functional 8 (5.4)
Other 3 (2.0)
Colonization with MDRO 7 (4.8)
Guideline-accordant prophylaxis 116 (78.9)
Correct choice 134 (91.2)
Correct dose 124 (92.5)
Administration < 60 min prior to incision 142 (91.2)
Type of diversion
Ileal conduit 120 (81.6)
Hautmann neobladder 27 (18.4)
Duration surgery, minutes 216 (75)
Blood loss, ml 1031 (700)
Abbreviations: ASA American Society of Anesthesiologists, BMI body mass
index, IQR interquartile range, MDRO multidrug resistant microorganism, SD
standard deviation
Fig. 1 Incidence and distribution in time of the post-operative infections
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Enterobacteriaceae plus P. aeruginosa are shown in Fig.
2b. Enterococci were cultured in 16 (24.2%) of 66 isolates
and 75% of the isolates were susceptible to AMX and
100% to VAN. S. aureus formed 9.1% of cultured bacteria
and 100% were methicillin susceptible.
Infections after ureteral stent removal
In the 24 h after ureteral stent removal, which was generally
performed on post-operative day 7 through 10 (85.7%), 7
patients developed a bacteremia. This was 25.9% of all pa-
tients with a bacteremia found in this study. Six of 7 blood
cultures (85.7%) grew Enterobacteriaceae, 1 blood culture
grew B. fragilis (Table 4). In addition, 16 patients developed
a complicated UTI within 24 h after ureteral stent removal.
This was 37.2% of all episodes of cUTI found in this study.
The 16 positive urine cultures grew a total of 24
micro-organisms (16 [66.7%] Enterobacteriaceae, 5
[20.8%] enterococci, 2 [8.3%] were S. aureus and 1
[4.2%] P. aeruginosa) (Table 4). Susceptibilities of the
Enterobacteriaceae plus Pseudomonas from both urine
and blood culture isolates are shown in Fig. 2c.
Outcome and risk factors for post-operative infections
Six patients (4.1%) required surgical treatment, and 8 pa-
tients (5.4%) were admitted to the ICU as a result of the
infection. The median duration of admission was 14 days
(IQR 5 days) and the 30-day mortality rate was 1.4%
(n = 2), one of whom died of sepsis. In univariate ana-
lysis, type of diversion (NB) and MDRO colonization
prior to surgery were associated with post-operative in-
fections (Additional file 1: Table S1). Multivariate logistic
regression analysis showed only NB to be associated
with increased infections complications: odds ratio 4.1
(95% confidence interval 1.6–10.5), p = 0.03.
Table 3 Urine and blood culture isolates from patients with post-operative infections
Bacteria Urine culture isolates, n (%) Blood culture isolates, n (%)
Enterobacteriaceae 41 (62.1) 19 (67.9)
Escherichia coli 14 (34.2) 8 (42.1)
Klebsiella pneumoniae 9 (22.0) 5 (26.3)
Enterobacter spp. 13 (31.7) 4 (21.0)
Proteus mirabilis 0 (0) 1 (5.3)
Serratia marcescens 1 (2.4) 1(5.3)
Morganella morganii 1 (2.4) 0
Citrobacter spp. 2 (4.9) 0
Hafnia alvei 1 (2.4) 0
Pseudomonas aeruginosa 3 (4.6) 0
Enterococci 16 (24.2) 5 (17.9)
Staphylococcus aureus 6 (9.1) 3 (10.7)
Bacteroides fragilis 0 1 (3.5)
Total 66 (100) 28 (100)
Fig. 2 Susceptibility patterns of Enterobacteriaceae and P.aeruginosa
isolated from (a) blood (b) urine, and from (c) urine in patients with
a complicated urinary tract infection 24 h within stent removal.
Susceptibility is shown in green, resistance in red. Number in the
green bars represents susceptibility percentage
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Discussion
This study showed a high incidence of post-operative in-
fections after radical cystectomy and urinary diversion
surgery. Post-operative infections peaked at day 4–5.
Furthermore, stent removal (around day 7–10) was asso-
ciated with the occurrence of bacteremia and cUTI. The
cultured gram-negative bacteria in urine and blood sam-
ples largely showed an inferred resistance to the used
antibiotic prophylaxis regimen consisting of cefazolin.
These findings question the timing and choice of cefazo-
lin, currently the most used agent, as surgical antibiotic
prophylaxis in radical cystectomy [13–16].
The assessment of etiology and antibiotic susceptibility
of post-operative infections characteristics in this study
enabled us to broaden the spectrum of antibiotic
prophylaxis for radical cystectomy in our hospital to pi-
peracillin/tazobactam and also administer empirical anti-
biotic prophylaxis just before removal of the ureteral
stents. A detailed analysis of the etiology and antibiotic
susceptibility of urine and blood isolates does highlight
the importance of selecting prophylaxis using the local
resistance data. Therefore, this study is an illustrative ex-
ample that a local guideline should be adapted to local
epidemiology of resistance [12, 21]. Another strength of
this study is the involvement of stakeholders, as recom-
mended by The Appraisal of Guidelines for REsearch &
Evaluation (AGREE) Instrument, a methodological strategy
for the development of guidelines [22]. As professional tak-
ing care of the target population, the urologist noticed the
high incidence of post-operative infections and also hypoth-
esized the relationship with stent removal. Subsequently,
the collaboration with a clinical microbiologist and infec-
tious disease specialist enabled the current study and the
development of a new guideline. Importantly, the involve-
ment of the prescribing professional, i.e. the urologist, leads
to an increased confidence in and facilitates a better imple-
mentation of and adherence to a new guideline [22].
Several studies assessed the risk of early post-operative
infections after radical cystectomy, showing high inci-
dences but large differences in reported post-operative
infection rates. [4–11] In our study, bacteremia was
found in 18%, SSI in 8.2% and cUTI in 28% of patients.
Rates of early post-operative bacteremia, SSI and UTI
(< 30 days) in other studies varied between 5 to 17%, 8
to 33% and 4 to 36%, respectively. [5, 9–11] One explan-
ation for the large differences in reported incidences of
post-operative infections after radical cystectomy might
be the different types of antibiotic prophylaxis regimens
used in different studies. Pariser et al. showed that type
of peri-operative antibiotic prophylaxis regimen might
have significant effect on infection outcomes after rad-
ical cystectomy [7], which was also found in two other
studies that analyzed post-operative infections within 90
days after UDS [14, 23]. A recent cohort study in 8351
patients from 353 hospitals in the United States showed
that 579 unique peri-operative antibiotic prophylaxis
regimens were used. Only 28% of patients received
prophylaxis according to the guideline [14]. Also, the
diagnosis of cUTI in patients with urinary diversion is
complicated by its vague presentation and lack of a stan-
dardized definition in the literature. Even though in our
study we only diagnosed cUTI when fever (≥ 38.5 °C)
could not be explained by SSI or bacteremia (and urine
culture showed ≥105 CFU/ml bacteria), we are aware
that we might have over reported the amount of cUTI in
this study as fever and bacteriuria are common after
UDS surgery.
This study particularly focused on the temporal rela-
tionship of post-operative infections and the removal of
the ureteral stents. To the best of our knowledge, this is
Table 4 Urine and blood culture isolates within 24 h after ureteral stent removal
Bacteria Urine culture isolates, n (%) Blood culture isolates, n (%)
Enterobacteriaceae 16(66.7) 6 (85.7)
Escherichia coli 4(25.0) 3(50.0)
Klebsiella pneumoniae 2(12.5) 1 (16.7)
Enterobacter spp. 8(50.0) 2(33.3)
Proteus mirabilis 0 0
Serratia marcescens 0 0
Morganella morganii 1(6.25) 0
Citrobacter spp. 1(6.25) 0
Pseudomonas aeruginosa 1(4.2) 0
Enterococci 5(20.8) 0
Staphylococcus aureus 2(8.3) 0
Bacteroides fragilis 0 1 (14.3)
Total 24 (100) 7 (100)
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the first study that assessed the etiology and antimicro-
bial susceptibility of bacteria cultured from blood and
urine within 24 h after stent removal. We found that
26% of all episodes of bacteremia and 37% of all episodes
of cUTI occurred within 24 h after ureteral stent re-
moval. Current guidelines do not recommend on the
need and type of antibiotic prophylaxis during ureteral
stent removal after UDS [13, 15, 16]. Most probably be-
cause the temporal relationship between infection and
ureteral stent removal has not been investigated thor-
oughly, as we could only find two previous studies on
this topic [10, 24]. Recently, Werntz et al. analyzed the
difference in post-operative infectious complications be-
tween 42 patients that received peri-operative and 42 pa-
tients that received peri-operative plus extended (30
days) antibiotic prophylaxis after UDS. [10] They found
that 30% of patients that received peri-operative prophy-
laxis only developed a cUTI one day after ureteral stent
removal compared to none of the patients in the group
that received extended prophylaxis. In a retrospective
study performed by Hashimoto et al., prophylactic ad-
ministration of antibiotics just before stent removal sig-
nificantly reduced the incidence of febrile events after
removal of ureteral stents [24]. Given the high incidence
of bacteremia and cUTI within 24 h after stent removal
in our study, we believe that, based on the results of this
study, antibiotic prophylaxis during ureteral stent re-
moval might reduce post-operative infections after UDS.
We encourage administration of a single dose of prophy-
laxis just before ureteral stent removal rather than ex-
tended post-operative antimicrobial prophylaxis, which
was administered by Werntz et al. in their study, as this
may lead to the development of antimicrobial resistance.
[13, 16] However, due to the retrospective and single
center design of our study, we feel these findings need to
be confirmed in a future prospective randomised clinical
trial.
This study has several limitations. The variables of inter-
est were collected retrospectively, which brings along the
risk of missing data. However, the outcome parameters are
recorded in our EMR and laboratory systems as discrete
variables that can be retrieved easily, reducing the risk.
Whether a patient is colonized with MDRO was not sys-
tematically assessed prior to the operation in most patients,
limiting the possibility to draw a conclusion on tailoring
prophylaxis to carrier state or structural screening for car-
rier state of MDRO. Another limitation is that this is a sin-
gle center study in a country with (relatively) low-level
resistance of Enterobacteriaceae. Ideally, the effect of a
change in antibiotic prophylaxis regimen should be exam-
ined in a robustly designed clinical follow-up study. A final
limitation of the study is that the susceptibility of Entero-
bacteriaceae to cefazolin was not tested as EUCAST break-
points for cefazolin do not exist. The susceptibility of
Enterobacteriaceae to cefazolin is roughly comparable to
the susceptibility to AMX and second generation cephalo-
sporins [25], implying that cefazolin does not cover the ma-
jority of Enterobacteriaceae that caused the post-operative
infections found in this study.
Conclusions
A detailed analysis of the incidence, etiology, and timing
of infections following radical cystectomy showed high in-
cidence of post-operative infections after radical cystec-
tomy and urinary diversion surgery. Notably, we identified
a peak in bacteremia and complicated UTI immediately
after stent removal. We believe that administration of
antibiotic prophylaxis just before stent removal might help
to reduce post-operative infections, although this needs to
be confirmed in future robust clinical trials before (inter)-
national guidelines should be altered. Our study empha-
sizes that local guidelines should be adapted to local
epidemiology of resistance, and that increased antimicro-
bial resistance necessitates a prophylactic regimen with in-
creased gram-negative coverage in radical cystectomy.
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